SCHEMBL368264

SCHEMBL368264

CC(C)(C)OC(=O)N1CCN(c2cc(N3CCOCC3)cn3c(=O)c(O)c(C(=O)NCc4ccc(F)cc4)nc23)C(=O)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
ENPP2 Q13822 2/20 0.41
CYP2C19 P33261 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KIT P10721 1/20 0.37
KCNE1 P15382 1/20 0.37
CCR1 P32246 1/20 0.37
KCNQ1 P51787 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE7A Q13946 1/20 0.37
CNR2 P34972 1/20 0.36
NAMPT P43490 1/20 0.36
CYP2C9 P11712 2/20 0.36
TP53 P04637 2/20 0.36
KCNH2 Q12809 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15101666 0.94 ENPP2 (0.42) SMN1; SMN2LMNAMAPTENPP2CYP2C19
SCHEMBL15101330 0.90 ENPP2 (0.38) SMN1; SMN2LMNAMAPTENPP2CYP2C19
SCHEMBL367914 0.88 PSMD14 (0.41) SMN1; SMN2LMNAMAPTCYP2C19NPSR1
SCHEMBL359476 0.85 PSMD14 (0.45) LMNACYP2C19KMT2AKCNE1CCR1
SCHEMBL10070053 0.84 SMN1; SMN2 (0.42) SMN1; SMN2LMNAMAPTENPP2CYP2C19
SCHEMBL10069922 0.84 ENPP2 (0.39) SMN1; SMN2LMNAMAPTENPP2CYP2C19
SCHEMBL10071007 0.83 ENPP2 (0.39) SMN1; SMN2LMNAMAPTENPP2CYP2C19
SCHEMBL367968 0.83 TP53 (0.42) SMN1; SMN2LMNAMAPTENPP2CYP2C19
SCHEMBL371325 0.83 PSMD14 (0.40) SMN1; SMN2LMNAMAPTCYP2C19NPSR1
SCHEMBL15092108 0.83 TP53 (0.40) SMN1; SMN2LMNAMAPTENPP2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) 2013-07-11 US disclosed
EP-2593460-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS Avexa Limited (AU) 2013-05-22 EP disclosed
WO-2012006680-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS AVEXA LIMITED (AU) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS EIF2AK2, IFNAR1, IRF3 SMN1; SMN2 2192/4885LMNA 4293/4885MAPT 4213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.